CeriBell (NASDAQ:CBLL) Director Josef Parvizi Sells 25,000 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Josef Parvizi sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $21.49, for a total transaction of $537,250.00. Following the completion of the transaction, the director owned 772,652 shares in the company, valued at $16,604,291.48. This represents a 3.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Josef Parvizi also recently made the following trade(s):

• On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $20.26, for a total value of $506,500.00.

CeriBell Trading Up 0.1%

Shares of NASDAQ CBLL traded up $0.03 during midday trading on Thursday, hitting $21.62. 5,558 shares of the company traded hands, compared to its average volume of 316,774. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65. The firm has a market cap of $801.92 million, a P/E ratio of -14.30 and a beta of 1.35. The stock has a 50-day moving average price of $14.90 and a 200 day moving average price of $14.61. CeriBell, Inc. has a 12-month low of $10.01 and a 12-month high of $28.23.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. The company had revenue of $22.59 million during the quarter, compared to analysts’ expectations of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. As a group, analysts expect that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on CBLL shares. TD Cowen decreased their target price on CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Weiss Ratings restated a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. Canaccord Genuity Group lifted their price target on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday. Cowen reissued a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Finally, Raymond James Financial began coverage on CeriBell in a research note on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. raised its position in shares of CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after acquiring an additional 1,256 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CeriBell in the third quarter valued at approximately $33,000. Rhumbline Advisers increased its stake in shares of CeriBell by 26.5% in the first quarter. Rhumbline Advisers now owns 15,629 shares of the company’s stock worth $300,000 after acquiring an additional 3,276 shares during the period. Finally, Sei Investments Co. raised its stake in shares of CeriBell by 7.1% during the 3rd quarter. Sei Investments Co. now owns 50,454 shares of the company’s stock valued at $580,000 after buying an additional 3,365 shares during the last quarter.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.